STRYKER CORP

Stryker Corporation designs, manufactures and sells medical‑technology products across two core businesses: MedSurg & Neurotechnology and Orthopaedics. Its offerings include surgical instruments and endoscopy systems, neurovascular and cranial devices, orthopedic implants and robotic‑assisted surgery platforms; revenue is driven mainly by product sales, recurring consumables and service/installation contracts, supported by targeted acquisitions.^[1]

Business Segments

• MedSurg & Neurotechnology — surgical instruments, endoscopy/communication systems, patient‑handling and neurovascular/cranial products; represents roughly 60% of consolidated net sales per company filings.^[2]
• Orthopaedics — joint implants (hip, knee, shoulder), trauma & extremities and spine products plus orthopedic robotics (Mako); accounts for about 40% of net sales.^[2]
• Geographic mix — the business generates the majority of revenue from the U.S. with the remainder from international markets (U.S. roughly three quarters of net sales, international about one quarter in the most recent filing).^[2]

Competitive Position

• Broad, complementary portfolio and scale — Stryker is a top competitor in reconstructive implants and operating‑room equipment, enabling cross‑sell and scale advantages across hospitals and health systems.^[3]
• Durable switching costs and installed base — surgeon familiarity with implants, long product life cycles and installed robotics/service relationships create high switching frictions and recurring revenue potential.^[4]

Investment Considerations

• Opportunity: aging populations and growing procedural volumes support steady demand for implants and surgical devices; adoption of robotics and neurovascular tools can expand long‑run margins and pricing power.^[5]
• Risk: heavy regulation, product‑liability exposure and evolving device approval standards can impose compliance costs, recalls or litigation that materially affect cash flows.^[2]
• Strategic tradeoffs: management’s use of acquisitions to accelerate growth can boost capabilities but increases goodwill and integration risk; investors should weigh M&A benefits against potential dilution or execution risk.^[6]
• Structural sensitivity: global supply‑chain disruptions, trade measures and currency fluctuations can affect manufacturing costs and international revenue; diversification and operational execution are key mitigants.^[2]